Is the price fair?
What PAHC's price assumes
Phibro Animal Health Corporation trades at 15.4× earnings against 24.4× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
15.4
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.4 · cheaper than the typical name in its group
- Price / sales
- 1.51
Price / sales · as of 2026-Q1
- Free cash flow yield
- 0.99%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- +27%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / book2026-Q1
- 6.25
- EV / EBIT2026-Q1
- 15.7
- EV / sales2026-Q1
- 1.88
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.4
- Free cash flow, trailing twelve months
- $13M
- Market capitalisation
- $1.29B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $40.34 |
| Its own P/E history, median | $45.48 |
| Its own P/E history, upper quartile | $51.73 |
| 52-week range | $27.75 – $59.33 |
| Today | $36.04 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #11 of 28 by Smart Score